BioCentury
ARTICLE | Company News

Aurigene, Curis deal

October 17, 2016 7:00 AM UTC

Curis exercised an option from Aurigene to license exclusive, worldwide rights outside India and Russia to preclinical oncology candidate CA-327 -- an oral small molecule antagonist of PD-L1 and T cell immunoglobulin and mucin domain 3 (TIM3; HAVCR2). ...